What is the difference between Opdivo and Keytruda?

Q: What is the difference between Opdivo and Keytruda?

The key differences between Opdivo (nivolumab) and Keytruda (pembrolizumab) are seen in the dosing frequency, the drugs they are used in combination with and the types of cancer they have been approved for use in.

Official answer

by Drugs.com

Opdivo (nivolumab) and Keytruda (pembrolizumab) are two immunotherapy drugs used to treat a number of different types of cancer. They are monoclonal antibodies that have similar efficacy and safety profiles and are both programmed death receptor-1 (PD1) inhibitors, which were first approved in the US in 2014.

Opdivo is marketed by Bristol Myers Squibb and Keytruda is marketed by Merck & Co.

The key differences between Opdivo and Keytruda are seen in the dosing frequency, the drugs they are used in combination with and the types of cancer they have been approved for use in.

Opdivo vs Keytruda: Dosing frequency

Opdivo is administered via a 30-60 min intravenous (IV) infusion every 2-4 or 6 weeks, whereas Keytruda is administered slightly less frequently. Keytruda is administered via a 30 min IV infusion every 3-6 weeks.

Opdivo vs Keytruda: Combination therapy

When used in combination with other drugs, Opdivo is used alongside:

Ipilimumab (Yervoy)

Platimum-doublet chemotherapy

Carbozantinib (Cabometyx)

When used in combination with other drugs, Keytruda is used alongside:

Pemetrexed (Alimta) and platinum chemotherapy

Carboplatin (Paraplatin) and either paclitaxel or paclitaxel protein-bound (Abraxane)

Platinum and flurouracil

Trastuzumab (Herceptin) plus fluoropyrimidine- and platinum-containing chemotherapy

Axitinib (Inlyta)

Lenvatinib (Lenvima)

Chemotherapy

Both drugs are also used alongside fluoropyrimidine- and platinum-containing chemotherapy for treating certain gastric cancers.

Opdivo vs Keytruda: Uses

Keytruda has been approved for use in a number of cancer types that Opdivo is not approved for use in including:

As a single-agent, first-line treatment for stage III or metastatic non-small cell lung cancer (NSCLC) expressing programmed death-ligand 1 (PD-L1). Both drugs are also approved for second-line therapy of NSCLC and in combination with other agents.

Primary mediastinal large B-cell lymphoma

Cervical cancer

Merkel cell carcinoma

Endometrial carcinoma

Tumor mutational burden-high cancer

Triple-negative breast cancer

On the other hand, Opdivo was the first to be approved for the adjuvant treatment of patients with high-risk urothelial carcinoma, although both Opdivo and Keytruda are used for treating other patients with advanced or metastatic urothelial carcinoma.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.